no news_id given

In case of queries, please contact

Dr. Karoline Stürmer Investor Relations Management Josef-Engert-Str. 11 93053 Regensburg Germany Phone: +49 (0)941 942 76-417 Fax:       +49 (0)941 942 76-711 ir@geneart.com www.geneart.com

Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49 (0)89 88 96 906-10 Fax:       +49 (0)89 88 96 906-66 info@better-orange.de www.better-orange.de

About GENEART AG  

In 2000 GENEART entered the Gene Synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. GENEART’s service portfolio ranges from the optimization and production of synthetic genes according to DIN EN ISO 9001:2008, to the generation of gene variants or complex gene libraries and the production of cell lines, to the development and production of DNA and protein based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about 180 people. The company is listed on the German Stock Exchange since May 2006. Since April 2010, the US-based Life Technologies Corporation, one of the leading biotechnology companies worldwide with 2009 revenues of 3.3B U.S. dollars and about 9,000 employees, is majority shareholder of GENEART AG.